Glp-1 Analogues Market Size, Share, By Product (Ozempic, Trulicity, Mounjaro, Xultophy, Victoza, Saxenda, and Others), By Drug Class (Semaglutide, Dulaglutide, Liraglutide, and Exenatide), By Route of Administration (Parenteral, and Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region - Trends, Analysis and Forecast till 2034

Glp-1 analogues market size was valued at USD 45.3 Billion in 2024 and is expected to reach USD 606.3 Billion by 2034, growing at a CAGR of 33%

GLP-1 analogues, otherwise known as GLP-1 receptor agonists, are a class of medicines mainly used for the treatment of type 2 diabetes and, lately, for weight management. According to some authors, these drugs work by replacing the action of glucagon-like peptide-1, which is a naturally occurring hormone in the human body that is important in the normal regulation of blood glucose and appetite. GLP-1 analogues stimulate the release of insulin from the pancreas in response to high blood glucose with associated retardation of gastric emptying and reduction in hunger through direct action on centers regulating hunger and satiety in the brain.

GLP-1 analogs seem to have the greatest efficacy in causing significant improvements in glycemic control for patients with type 2 diabetes, with resultant reductions of 1-2% in HbA1c, a measure for long-term blood sugar control. In addition, these medications show huge benefits in weight reduction; for instance, some patients may lose 5-15% or more of their initial body weight. It is in these dual actions on blood sugar and weight that GLP-1 analogs have proved to be particularly useful in treating patients with both diabetes and obesity; these co-occur in many instances. In addition, the effects of GLP-1 analogues on blood sugar and weight seem to exhibit some potential cardiovascular benefits. Several large-scale clinical trials demonstrated that such medications could lower the rate of major adverse cardiovascular events in patients receiving these medications, making them, under certain situations, cardioprotective agents. Such findings have expanded the role of GLP-1 analogues from diabetes to lowering cardiovascular risk in some patients.

Recent interest in GLP-1 analogs is an outgrowth of the success they have had in the treatment of diabetes and obesity. Active research is going on in their use on neurodegenerative diseases like Alzheimer's, nonalcoholic fatty liver disease, and even some forms of cancer. Thirdly, with a better understanding of these medications, their role in medical treatment is changing, perhaps offering new therapeutic options for various health conditions.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Key Drivers of Target Market:

Growing Cases of Type 2 Diabetes and Obesity:

• The rising cases of type 2 diabetes and obesity worldwide are some of the key drivers for the GLP-1 analogues market. The two conditions are closely related; obesity is one of the major risk factors for the development of type 2 diabetes. The increasing prevalence of metabolic disorders has resulted in the growing demand for better treatment options, thereby including GLP-1 analogs. Moreover, aging populations in most countries are another reason for their ever-increasing cases, thus fueling market growth.

Rising Awareness about Benefits of GLP-1 Analogues:

• This has seen tremendous growth in awareness amongst treating physicians and patients about the advantages of GLP-1 analogues. The drugs have been at par in glucose control and inducing weight loss, reducing cardiovascular risk, and improving other metabolic parameters. This growing understanding of their therapeutic potential has been driving the market growth.

Restrains:

Side Effects and Safety Concerns:

• While the efficacy in the management of type 2 diabetes and obesity with GLP-1 analogues has been paramount, they are not devoid of side effects. The commonly reported adverse drug reactions are nausea, vomiting, diarrhea, and hypoglycemia. The more serious ones, though less common, are pancreatitis and thyroid C-cell tumors. These safety concerns will dissuade patients from commencing or continuing treatment and negatively affect market growth. The long-term safety profile of these drugs is yet to be spelled out to ease patient fears and engender trust.

Opportunities:

Expanding Therapeutic Indications:

• The huge potential for GLP-1 analogue drugs exists outside diabetes management. These drugs have shown remarkable efficacy in weight loss, opening up a large market for treating obesity. Other potentials like reduced cardiovascular risk and actions against non-alcoholic steatohepatitis are also large markets open to this group of drugs. These therapeutic indications represent opportunities for companies to leverage and explore new patient populations that will drive market growth.

The market is segmented based on Product, Drug Class, Route of Administration, Distribution Channel, and Region.

Product Insights:

• Ozempic: Ozempic is one of the most popular GLP-1 analogues, largely prescribed in the treatment and management of type 2 diabetes. Developed by Novo Nordisk, it acts as a replacement for the incretin hormone, thus stimulating insulin secretion. The medicine is preferred for diabetics because it can lower blood sugar and help with weight management, thereby providing holistic treatment for diabetes.
• Trulicity: Trulicity from Eli Lilly makes treatment feasible at a once-weekly dosing frequency. This further leads to better patient adherence to treatment regimens. There is robust performance in the treatment of glycaemic control and proof of cardiovascular benefit, thus giving this drug an added advantage in being used for diabetic patients.
• Mounjaro: Mounjaro is the new player in the market that combines the good aspects of GLP-1 and GIP receptor agonism. The two concomitant mechanisms lead to enhanced glucose control and marked weight loss, and attention is drawn toward Mounjaro as a novel confluence of ideas into the multitude of opportunities opened for the integrated management of diabetes and obesity.
• Xultophy: Xultophy is a fixed-ratio combination of insulin degludec and liraglutide. This product merges the benefits of long-acting insulin with the advantages of a GLP-1 analogue, providing a synergistic effect that significantly improves blood sugar control. Xultophy’s dual action targets both fasting and postprandial glucose levels, making it a versatile option for diabetes patients.
• Victoza: A daily injection of GLP-1 analogue, Victoza from Novo Nordisk, has been well researched and is proven to reduce HbA1c levels while helping patients lose weight. It also brings cardiovascular benefits to the table, making it imperative for general practitioners to take a more cohesive approach to patient care.
• Saxenda: This is mainly used for weight management rather than diabetes. It was developed by Novo Nordisk. It contains liraglutide, which works as an appetite suppressant and helps reduce food intake, which in turn brings about substantial weight loss in obese patients. As such, Saxenda is often prescribed for some weight-related health issues in patients and is important in the entire market for GLP-1 analogues.
• Others: This is a group of GLP-1 analogs that exist in the market but are less popular than many others. In most cases, they mainly serve market niches or are in the pipeline for further developments, thus further diversifying the alternatives available in diabetes and weight management. This again further proves the dynamism and research done on GLP-1 analogs.

Drug Class Insights:

• Semaglutide: A major GLP-1RA analog, Semaglutide is one of the most potent in controlling blood sugar levels and inducing weight loss. It can be taken either orally (Rybelsus) or in an injectable form (Ozempic) with dose-up flexibility. Due to its relatively longer half-life, semaglutide has a sustained effect, increasing patient compliance.
• Dulaglutide: Administered weekly, dulaglutide has the added advantage of enhanced compliance among patients. It is very potent, with vigorous GLP-1 analogue activity that can improve HbA1c levels and enhance cardiovascular health. This easy delivery, added to the strong clinical effect, makes it adorable to many healthcare providers and patients.
• Liraglutide: It is another GLP-1 analogue that has a versatile role in the management of diabetes. It reduces weight, working as Victoza does. It has been through much research on positive effects on glycemic control, weight reduction, and cardiovascular outcomes. Hence, it is a sweeping indication and the proof of its efficacy makes it a backstone in the market of GLP-1 analogues.
• Exenatide: One of the earliest GLP-1 analogs to be developed, exenatide is now commercially available in both short-acting (Byetta) and long-acting (Bydureon) preparations. It increases the secretion of insulin while lowering the release of glucagon via the duplication of the incretin hormone. Exenatide in dual formulations hence upholds flexibility in treatment regimens, thereby answering different patient needs and preference demands.

Route of Administration Insights:

• Parenteral: GLP-1 analogues are mostly given this way, referring to the use of injections. This route ensures a very immediate and effective way of introducing medication into the bloodstream and renders fast therapeutic action. Most GLP-1 analogues, including Ozempic, Trulicity, and Victoza, are administered parenterally, highlighting their importance in the market.
• Oral: Although a relatively new route of administration, it has been more comfortable for patient use, with molecules like Rybelsus (Semaglutide) leading the way. Patient compliance is increased with this route as there is no need for an injection. Therefore, the oral route of administration of GLP-1 analogues is especially attractive to patients with an aversion to needles, thus broadening the market reach for increased accessibility.

Distribution Channel Insights:

• Hospital Pharmacies: GLP-1 analogues are largely distributed in a hospital pharmacy setup, mainly for inpatients and those who need initial training related to injection techniques. Such pharmacies may stock medications for acute care and can provide patient education on proper usage.
• Retail Pharmacies: They are the main distribution channel for GLP-1 analogues and thus easily accessible to outpatients. They are convenient, and accessible, and offer the advantages of picking up medications during regular trips and getting consultations from pharmacists.
• Online Pharmacies: Online pharmacies are fast becoming an increasingly common method of sale or distribution channel for GLP-1 analogues. They bring the comfort of your own home and often competitive pricing. This option will turn out to be especially useful for those with some mobility issues or living in remote areas.

Regional Insights

• North America: The rising prevalence of diabetes and obesity, especially in the United States, makes North America a market leader in GLP-1 analogues. This region has advanced healthcare infrastructure, massive investments in R&D, and good awareness about diabetes management. Robust insurance coverage and favorable reimbursement policies further support market growth in this region.
• Asia Pacific: The GLP-1 analogue market is fast-tracking in this region of the Asia Pacific owing to the rising cases of diabetes, elevating expenditure on health care, and access to high-end treatments. China, India, and Japan are some of the key markets in this region where the healthcare infrastructure is presently on the rise. Thus growing awareness about the therapy for diabetes management fuels market growth.
• Europe: Europe is another high-potential market for GLP-1 analogues, driven by countries such as Germany, the UK, and France. Focus on quality healthcare, high acceptance of new treatments, and a well-developed healthcare infrastructure are some factors supporting the growth of the GLP-1 analogue market in the region. European regulatory bodies are also encouraging the use of therapies that can effectively manage diabetes.
• Latin America: This region in the GLP-1 analogue market is growing, especially in countries such as Brazil and Mexico. The region has a heightened burden of diabetes and obesity that requires effective treatment options. Access to improved healthcare facilities, improvements in disposable incomes, and growing awareness about diabetes care are some major drivers of the market in Latin America.
• Middle East and Africa: This region is a gradual starter in the uptake of GLP-1 analogs, with a rise in diabetes cases and an attempt to build up healthcare infrastructure. Countries like Saudi Arabia, UAE, and South Africa are working toward better diabetes care, which is impelled by government initiatives and investment in healthcare. Access and other such constraints are being worked on to broaden the market scope in this region.

Glp-1 Analogues Market Report Scope:

Attribute	Details
Market Size 2024	USD 45.3 Billion
Projected Market Size 2034	USD 606.3 Billion
CAGR Growth Rate	33%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Product - Ozempic, Trulicity, Mounjaro, Xultophy, Victoza, Saxenda, and Others. By Drug Class - Semaglutide, Dulaglutide, Liraglutide, and Exenatide. By Route of Administration - Parenteral, and Oral By Distribution Channel - Hospitals, Ambulatory Surgical Centers, Retail Pharmacies, and Others.
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on Product, Drug Class, Distribution Channel, and Region.

Segmentation:

By Product:

• Ozempic
• Trulicity
• Mounjaro
• Victoza
• Saxenda
• Others

By Drug Class:

• Semaglutide
• Dulaglutide
• Liraglutide
• Exenatide

By Route of Administration:

• Parenteral
• Oral

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Glp-1 Analogues Market Novo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Pfizer.Inc, Amgen, Inc., Innovent Biologics, Inc., PegBio Co., Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Zealand Pharma, Moderna, Hanmi Science.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

• Viking's new dual GLP-1R/GIPR agonist is expected to begin clinical trials in phase III shortly, in July 2024. VK2735 could be a direct competitor to Eli Lilly's Mounjaro. Viking Therapeutics, an American biopharmaceutical business, is developing numerous candidates to treat metabolic diseases. VK2735, a dual glucagon-like peptide-1 receptor (GLP-1R)/gastric inhibitory polypeptide (GIP) receptor agonist, is being studied as both a weekly subcutaneous (SC) injection and an oral tablet for the treatment of obesity.
• In July 2024, The MHRA approved Semaglutide, a GLP-1 receptor agonist, to reduce the risk of significant heart issues in obese or overweight people. Semaglutide is the first weight-loss medication licensed in the United Kingdom as a prophylactic treatment for people with existing cardiovascular disease. This drug, a GLP-1 receptor agonist, is already approved for treating obesity and weight management in conjunction with diet, physical activity, and behavioral support.
• In February 2024, Herbalife, a leading health and wellness company and community, announced the launch of the Herbalife GLP-1 Nutrition Companion, a new line of food and supplement product combinations powered by the #1 Protein Shake in the World* and designed to meet the nutritional needs of people taking GLP-1 and other weight-loss medications. Herbalife's Classic and Vegan tastes are now available in the United States and Puerto Rico.

• Novo Nordisk A/S*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Eli Lilly and Company
• Sanofi
• AstraZeneca
• Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
• Pfizer.Inc
• Amgen, Inc.
• Innovent Biologics, Inc.
• PegBio Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Zealand Pharma
• Moderna
• Hanmi Science

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

      Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Product
  • Market Snippet, By Drug Class
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, Product, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Ozempic
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Trulicity
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Mounjaro
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Xultophy
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Victoza
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Saxenda
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, Drug Class, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Semaglutide
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Dulaglutide
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Liraglutide
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Exenatide
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, Route of Administration, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Parenteral
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Oral
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, Distribution Channel, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Retail Pharmacies
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Online Pharmacies
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Region, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (USD Bn), By Product, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • U.S
    • Canada
• Asia Pacific
  • Market Size and Forecast (USD Bn), By Product, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Europe
  • Market Size and Forecast (USD Bn), By Product, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • UK
    • Germany
    • France
    • Russia
    • Italy
    • Rest of Europe
• Latin America
  • Market Size and Forecast (USD Bn), By Product, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Market Size and Forecast (USD Bn), By Product, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East and Africa

Competitive Landscape

• Heat Map Analysis
• Company Profiles

• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi
• AstraZeneca
• Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
• Pfizer.Inc
• Amgen, Inc.
• Innovent Biologics, Inc.
• PegBio Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Zealand Pharma
• Moderna
• Hanmi Science

The Last Word

• Future Impact
• About Us
• Contact